

NEOSE TECHNOLOGIES INC  
Form 8-K  
October 21, 2003

---

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): October 21, 2003**

---

**Neose Technologies, Inc.**

(Exact name of issuer as specified in charter)

**DELAWARE**  
(State or Other Jurisdiction of  
Incorporation or Organization)

**0-27718**  
(Commission file  
number)

**13-3549286**  
(I.R.S. Employer  
Identification  
Number)

**102 Witmer Road,**  
**Horsham, Pennsylvania 19044**  
(Address of principal executive offices)

**(215) 315-9000**  
(Registrant's telephone number, including area code)

---

**Item 5 Other Events.**

On October 21, 2003, the Company announced that it is developing an improved, GlycoPEGylated version of granulocyte colony stimulating factor (G-CSF) as its second proprietary protein. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

**Item 7 Financial Statements, Pro Forma Financial Information and Exhibits.**

- (a) Financial Statements of Businesses Acquired: None
- (b) Pro Forma Financial Information: None
- (c) Exhibits: Reference is made to the Exhibit Index annexed hereto and made a part hereof.

**Signatures**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

**Neose Technologies, Inc.**

Date: October 21, 2003

By:

/s/ C. BOYD CLARKE

---

C. Boyd Clarke  
President and Chief Executive Officer

**Index to Exhibits**

<u>Exhibit No.</u>	<u>Description</u>
Exhibit 99.1	Press Release dated October 21, 2003